Table 1.
Initial meta-analyses of pyrazinamide susceptibility testing methods in culture isolates of M. tuberculosisa
| Assay category | No. of data sets | No. of resistant strainsb | No. of susceptible strainsb | Mean value (95% CI) |
Funnel plot asymmetry (P value) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity (%) | Specificity (%) | Positive LR | Negative LR | DOR | |||||
| PCR-DNA sequencing | 29 | 998 | 1,207 | 87 (82–91) | 93 (89–96) | 12.9 (7.6–22.0) | 0.14 (0.09–0.21) | 93 (48–181) | 0.04 |
| PCR-SSCPc | 5 | 228 | 261 | 75 (53–88) | 95 (83–98) | 14.1 (3.9–51.0) | 0.27 (0.11–0.66) | 53 (11–254) | 0.56 |
| Molecular assaysd | 6 | 198 | 416 | 96 (89–99) | 97 (89–99) | 28.9 (8.3–100.8) | 0.04 (0.01–0.12) | 756 (138–4,140) | 0.18 |
| Wayne assay | 33 | 1,141 | 2,052 | 89 (84–92) | 97 (95–98) | 27.8 (16.0–48.3) | 0.12 (0.08–0.17) | 237 (121–465) | 0.006 |
a
CI, confidence interval; DOR, diagnostic odds ratio; LR, likelihood ratio; SSCP, single-stranded conformation polymorphism.
b
Based on standard phenotypic drug susceptibility testing.
c
With or without multiplex PCR amplimer conformation analysis.
d
Comprises line probe assay, microarray, branch migration inhibition, denaturing gradient gel electrophoresis, and temperature-mediated heteroduplex analysis using denaturing high-performance liquid chromatography.